Document is current
Any future updates will be listed below
-
Authors
Shen, Minhong
Smith, Heath A.
Wei, Yong http://orcid.org/0000-0002-1034-649X
Jiang, Yi-Zhou
Zhao, Sheng
Wang, Nicole
Rowicki, Michelle
Tang, Yong
Hang, Xiang
Wu, Songyang
Wan, Liling
Shao, Zhi-Ming
Kang, Yibin http://orcid.org/0000-0002-1626-6730
-
Funding
Funding for this research was provided by:
U.S. Department of Defense (BC151403)
- License Information
-
More Information
Article History
Received: 20 October 2020
Accepted: 23 September 2021
First Online: 29 November 2021
Competing interests
: Princeton has filed a disclosure on the findings based on this study. Y.K. and M.S. are named as co-inventors on the disclosure. Y.K. is a cofounder and chair of the Scientific Advisory Board of Firebrand Therapeutics, which is currently developing new therapeutics based on the targeting of MTDH–SND1 and has licensed relevant technologies from Princeton University. Y.K. is also a cofounder of Kayothera and a member of the Scientific Advisory Board for Cytocare and Vibrant Pharma Limited. The other authors declare no competing interests.
